

国内版 国际版

Longitudinal decrease in platelet counts as a surrogate



ALL IMAGES VIDEOS

Add the Give with Bing extension >

140,000 Results Any time ▾

Post hoc analyses of surrogate markers of non ... - BMJ Open

<https://bmjopen.bmj.com/content/9/2/e023597>

Feb 01, 2019 · Objective One year of comprehensive continuous care intervention (CCI) through nutritional ketosis improves glycosylated haemoglobin(HbA1c), body weight and **liver** enzymes among patients with type 2 diabetes (T2D). Here, we report the effect of the CCI on **surrogate** scores of non-alcoholic fatty **liver** disease (NAFLD) and **liver fibrosis**. Methods This was a non-randomised **longitudinal** ...

Cited by: 7 Author: Eduardo Vilar-Gomez, Shaminie J Athinara...

Publish Year: 2019

Post hoc analyses of surrogate markers of non-alcoholic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398805>

Primary outcomes: NAFLD **liver** fat and **liver fibrosis** by non-invasive **surrogate markers** . N-LFS is a **surrogate marker** of fatty **liver** that includes the presence of the metabolic syndrome, T2D, fasting serum insulin, AST and the AST/ALT ratio.

Cited by: 7 Author: Eduardo Vilar-Gomez, Shaminie J Athinara...

Publish Year: 2019

Non-invasive Markers of Liver Fibrosis: Adjuncts or ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913110>

Jun 20, 2016 · These factors, along with an acknowledgement of the need to stage disease without reliance on **liver** biopsy, have lead to an exponential interest in the identification and use of non-invasive **markers of liver fibrosis**. The performance of a non-invasive **marker of fibrosis** is measured using **liver** biopsy staging of **fibrosis** as the reference standard.

Cited by: 21 Author: Jun L. Chin, Michael Pavlides, Ahmad Mool...

Publish Year: 2016

Thrombocytopenia as a surrogate for cirrhosis and a marker ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.22242>

Platelet counts reflect the severity of **liver fibrosis**, as stated above. In a hospital-based study, changes in **platelet counts** were as a **marker** for the risk of developing HCC in patients with HCV-related cirrhosis. 32 Another problem that must be addressed is the proportion of patients with HCC who exhibit thrombocytopenia.

Cited by: 182 Author: Sheng-Nan Lu, Sheng-Nan Lu, Jing-Houng ...

Publish Year: 2006

Search Tools

Turn on Hover Translation (开启取词)

ALL IMAGES VIDEOS

105,000 Results Any time

Platelet indices significantly correlate with liver ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952095>

Jan 09, 2020 · Moreover, patients with **advanced liver fibrosis** had significantly **lower PLT counts** and significantly higher MPV, PDW and P-LCR values when compared with patients with **mild fibrosis**. These findings indicate that the **PLT count** and MPV, PDW and P-LCR indices can be used as **surrogate markers of fibrosis** progression or regression in HCV-infected patients.

Author: Lin-Nan Shao, Shu-Ting Zhang, Ni Wang... Publish Year: 2020

Platelet Counts and Liver Enzymes After Gastric Bypass Surgery

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973993>

Dec 08, 2017 · Yoneda et al. have used **liver biopsies** to evaluate the clinical usefulness of **measuring PCs** for predicting the **severity of liver fibrosis** in 1048 patients with NAFLD . They suggest **platelet count** to be a major biomarker for this purpose, as there is a **linear association** between **decreased PCs** and **increased fibrosis** in the **histopathology of liver**.

Cited by: 6 Author: Hans-Erik Johansson, Anna Wåhlén, Erica ... Publish Year: 2018

Platelet indices significantly correlate with liver ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0227544>

Jan 09, 2020 · It is noteworthy that the **PLT count** is also a convenient **marker of liver fibrosis** in several hepatic diseases, such as **nonalcoholic fatty liver disease** [8], hepatitis B [9] and C [10]. Nevertheless, there are studies reporting conflicting results [11, 12].

Author: Lin-Nan Shao, Shu-Ting Zhang, Ni Wang... Publish Year: 2020

[PDF] Platelet Counts and Liver Enzymes After Gastric Bypass Surgery

<https://link.springer.com/content/pdf/10.1007/s11695-017-3035-5.pdf>

Platelet count has been shown to be a valuable **surrogate marker** predicting the **severity of fibrosis** in NAFLD patients and could be used to predict the activity of the disease. Furthermore, high PCs are also related to cardiovascular death and all-cause mortality.

Cited by: 6 Author: Hans-Erik Johansson, Anna Wåhlén, Erica ... Publish Year: 2018

Magnetic resonance elastography to quantify liver disease ...

<https://link.springer.com/article/10.1007/s00261-020-02694-1>

Aug 05, 2020 · To evaluate whether **liver** and spleen magnetic resonance elastography (MRE) can measure the severity of congenital hepatic **fibrosis** (CHF) and portal hypertension (pHTN) in individuals with autosomal recessive polycystic kidney disease (ARPKD), and to examine correlations between **liver MRE** and ultrasound (US) elastography. Cross-sectional study of nine individuals with ARPKD and 14 ...

Author: Erum A. Hartung, Erum A. Hartung, Jua... Publish Year: 2020

The value of platelet count in evaluating the degree of ...

<https://onlinelibrary.wiley.com/doi/10.1002/jcla.23270>

Thrombocytopenia, with the definition of **lower platelet count** compare with normal limit, is a common symptom during the progress of **chronic liver disease**. 35, 36 Lu SN and Iida H et al 37, 38 also have reported that **decreased platelet count** is associated with **liver cirrhosis**. However, **platelet count** served as a single index to assess the progression of **hepatic fibrosis** and compare with other serological ...

Post hoc analyses of surrogate markers of non-alcoholic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398805>

Primary outcomes: NAFLD **liver fat** and **liver fibrosis** by non-invasive **surrogate markers** . N-LFS is a **surrogate marker** of **fatty liver** that includes the presence of the metabolic syndrome, T2D, fasting serum insulin, AST and the AST/ALT ratio.

Efficacy and HCC development after DAA therapy for ...

<https://hrjournal.net/article/view/2255>

The FIB4-index, which is a calculated hepatic **fibrosis marker**, was also significantly **decreased**. Moreover, alpha (α)-fetoprotein, which showed both **liver inflammation** and tumor **marker**, was significantly **decreased**. However, total bilirubin (T-bil), albumin and **platelet count** were not significantly changed after SVR24 .

Non-invasive Markers of Liver Fibrosis: Adjuncts or ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913110>

Jun 20, 2016 · These factors, along with an acknowledgement of the need to stage disease without reliance on **liver biopsy**, have lead to an exponential interest in the identification and use of non-invasive **markers of liver fibrosis**. The performance of a non-invasive **marker of fibrosis** is measured using **liver biopsy staging of fibrosis** as the reference standard.

Platelets in liver and renal disease

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142504>

Dec 02, 2016 · **Platelets** and ESRD. Patients with ESRD are prone to both bleeding and thrombosis. A major morbidity in ESRD is thrombosis, with more than half of all grafts developing thrombosis within 2 years, 23 and cardiovascular disease is a significant cause of mortality in these patients, accounting for 45% to 50% of deaths among patients on dialysis. 24 Paradoxically, 24% to 55% of patients with ESRD ...

Some results are removed in response to a notice of local law requirement. For more information, please see [here](#).

Search Tools

Turn off Hover Translation (关闭取词)

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 56897

Manuscript Type: ORIGINAL ARTICLE

Case Control Study

Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis

Gotlieb N *et al.* Platelets decline predict cirrhosis

Neta Gotlieb, ¹Naama Schwartz, Shira Zelber-Sagi, Gabriel Chodick, Varda Shalev, Oren Shibolet

Abstract

BACKGROUND

Liver cirrhosis ⁵is a significant source of morbidity and mortality worldwide. The disease is usually indolent and asymptomatic early in its course while many cirrhotic patients are diagnosed late when severe complications occur. A major challenge is to

Match Overview

Match Number	Source	Words	Similarity
1	Crossref "Posters (Abstracts 301-2389)", <i>Hepatology</i> , 2018	103 words	2%
2	Crossref "NAFLD and NASH", <i>Springer Science and Business Media LLC</i> , 2020	67 words	1%
3	Crossref Cheli Melzer-Cohen, Gabriel Chodick, Lise Lotte N. Husemoen, Nicolai Rhee, Varda Shalev, Avraham Karasik. "A	56 words	1%
4	Crossref "Posters (Abstracts 264-2239)", <i>Hepatology</i> , 2017	48 words	1%
5	Internet crawled on 09-Aug-2020 worldwidescience.org	46 words	1%
6	Internet crawled on 09-Apr-2019 jamanetwork.com	45 words	1%
7	Crossref Abhishek Chauhan, David H. Adams, Steve P. Watson, ... atricia F. Lalor. "Platelets: No longer bystanders in liver di	33 words	1%
8	Internet crawled on 17-May-2020 www.wjgnet.com	31 words	1%



ALL

IMAGES

VIDEOS

107,000 Results

Any time ▾

Post hoc analyses of surrogate markers of non-alcoholic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398805>

Primary outcomes: NAFLD liver fat and liver fibrosis by non-invasive surrogate markers . N-LFS is a surrogate marker of fatty liver that includes the presence of the metabolic syndrome, T2D, fasting serum insulin, AST and the AST/ALT ratio.

Cited by: 11

Author: Eduardo Vilar-Gomez, Shaminie J Athinar...

Publish Year: 2019

[PDF] Platelet Counts and Liver Enzymes After Gastric Bypass ...

<https://link.springer.com/content/pdf/10.1007/s11695-017-3035-5.pdf>

Platelet count has been shown to be a valuable surrogate marker predicting the severity of fibrosis in NAFLD patients and could be used to predict the activity of the disease. Furthermore, high PCs are also related to cardiovascular death and all-cause mortality.

Cited by: 6

Author: Hans-Erik Johansson, Anna Wåhlén, Eric...

Publish Year: 2018

Thrombocytopenia as a surrogate for cirrhosis and a marker ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.22242>

Among the individuals who were positive for anti-HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was $150 \times 10^3 / \text{mm}^3$ for a diagnosis of cirrhosis.

Cited by: 183

Author: Sheng-Nan Lu, Sheng-Nan Lu, Jing-Houn...

Publish Year: 2006

Non-invasive assessment of liver fibrosis

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959378>

Feb 27, 2011 · Individual surrogate markers of liver fibrosis. Hepatic stellate cells (HSC) represent the dominant profibrogenic hepatic cell type. Activation and subsequent transformation in fibrogenic and contractile myofibroblasts is the key event leading to extracellular matrix (ECM) deposition and increased intrahepatic resistance to blood flow (portal hypertension).

Cited by: 113

Author: Vasilios Papastergiou, Emmanuel Tsocha...

Publish Year: 2012